Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors

Yuriko Nishiyama-Fujita, Tomonori Nakazato, Noriyoshi Iriyama, Michihide Tokuhira, Maho Ishikawa, Eriko Sato, Tomoiku Takaku, Keiji Sugimoto, Hiroyuki Fujita, Isao Fujioka, Shun Tsuchiya, Yuta Kimura, Eisaku Iwanaga, Norio Komatsu, Norio Asou, Masahiro Kizaki, Yoshihiro Hatta and Tatsuya Kawaguchi

**ABSTRACT**

**Introduction:** Few studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs).

**Materials and methods:** We retrospectively analysed the clinical features, treatment response, and long-term outcomes of 42 AYA patients, in comparison to older patients. The initial therapies of AYA patients between 2001 and 2016 included imatinib (n=24), dasatinib (n=13) and nilotinib (n=5).

**Results:** In AYA patients, the peripheral blood (PB) white blood cell count and percentage of blasts at the diagnosis were significantly higher, haemoglobin levels were lower and the spleen size was larger. The major molecular response (MMR), event-free survival (EFS) and overall survival (OS) rates were comparable. A sub-analysis comparing imatinib to second-generation TKIs as the initial therapy also showed that their prognosis was comparable.

**Discussion:** In conclusion, the tumour burden at the diagnosis of CML-CP is higher in AYA patients; however, their prognosis was not worse in comparison to older patients treated with TKIs.

**KEY MESSAGES**

Few studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs). This study showed the tumour burden at the diagnosis of CML-CP is higher in AYA patients; however, their prognosis was not worse in comparison to older patients treated with TKIs. Understanding the biological and non-biological features of AYA patients with CML-CP on TKI therapy is essential for better management and to improve the outcomes.
Many AYA patients continue to experience inferior outcomes in comparison to younger and older age groups for many reasons. One of the reasons is reported to be low clinical trial participation resulting in a low rate of tumour specimen acquisition for research [7,8]; thus, there is less understanding of the biological features in this patient population. Other reasons include fewer opportunities to receive medical check-ups, lack of standardized therapeutic approaches, poor compliance with therapy, psychosocial issues, including fertility preservation, contraception before the initiation of therapy, increased risk of mental health disorders, quality-of-life (QOL) issues, insurance or financial issues and the availability and identification of resources [9–11]. CML is no exception in this regard, and little is known about the outcomes of AYA patients with CML, particularly in the TKI era.

To our knowledge, few studies have precisely analysed the outcomes of AYA patients with CML-CP treated with TKIs, including the second-generation TKIs nilotinib and dasatinib [12–17]. We therefore retrospectively analysed the clinical characteristics and outcomes of AYA patients with CML-CP treated with TKIs and further evaluated the outcomes of AYA patients who were treated with nilotinib, and dasatinib.

Materials and methods

Patients

A retrospective review of data from the CML Cooperative Study Group, which includes four University Hospitals and four University Branch Hospitals, was performed. Our study included 360 patients of ≥18 years of age who were diagnosed with CML-CP between April 2001 and January 2016 and who were treated with any TKIs. CML-CP was diagnosed according to the European Leukaemia Net (ELN) criteria, as described previously [18]. Patients in the accelerated phase (AP) or blast phase (BP) were excluded from this study. As the majority of the reported studies have used 29 years of age as a cut-off value for AYAs in cohort analyses, we used a cut-off value of 29 years to improve the integrity of the scientific questions, including the patient characteristics, treatment response and long-term outcomes. The response criteria were as previously described [19]. An MMR was defined as a MAJOR BCR-ABL1 mRNA/ABL1 mRNA ratio of ≤0.1%, as determined by the International Scale (IS), and a DMR was defined as a MAJOR BCR-ABL1 mRNA/ABL1 mRNA ratio of ≤0.0032%, as determined by the IS. We could not collect details about the achievement of a complete cytogenetic response (CCyR) for all patients in this study. The study was approved by the ethics committees of all hospitals involved and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all the patients after fully explaining the nature of the study and that the information of the patients should not be identified. The grade of each side effect was based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (National Cancer Institute, Maryland, USA).

Statistical analyses

Differences among variables were evaluated by the χ² test and Mann–Whitney U test for categorical and continuous variables, respectively. OS was defined as the period between the date of the initial TKI treatment and the date of death due to any cause. EFS was measured from the start of the initial treatment to the date of any of the following events while on therapy: loss of a complete haematologic response, loss of a complete or major cytogenetic response, or progression to AP or BP, and death from any cause at any time. The probability of survival was estimated by the Kaplan–Meier method and compared by the log-rank test. The MMR and DMR were assessed, regardless of whether treatment agents were switched, and were evaluated as the probability of attaining an MMR or DMR at each time point. The comparison between the cumulative incidence of an MMR or DMR, or transformation to AP or BP was performed using the Grey test [20]. P values of <.05 were considered to indicate statistical significance. All statistical analyses were performed using the EZR software program [21].

Results

Patient characteristics

Data from 360 patients (male, n = 221 [61%]; female, n = 139 [39%]) were analysed. The median follow-up period was 67 months (range, 0–202 months). The median age at the time of the diagnosis of CML was 53.5 years (range, 18–86 years). A total of 182 patients were treated with imatinib, 80 were treated with nilotinib and 98 were treated with dasatinib as the initial treatment. The 360 patients were divided into two groups according to their age at the time of the diagnosis. Patients who were diagnosed with CML-CP at 18–29 years of age were classified into the AYA group (n = 42; 11.7%) and those who were diagnosed at ≥30 years of age were classified into the older group (n = 318; 88.3%). The demographics and baseline characteristics of the two patient groups are shown in
The AYA group showed a significantly larger spleen size ($p < .0001$), higher white blood cell count ($p < .0001$), a higher percentage of lymphocytes ($p = .008$), a higher percentage of blasts in peripheral blood (PB) ($p < .0001$), and a lower haemoglobin level ($p = .004$). They also showed higher probability of having a high-risk status according to the Sokal and Hasford scores ($p = .009$ and .001, respectively.) There was no difference in the percentages of eosinophils or basophils in the PB, the platelet count or the European Treatment and Outcomes Study (EUTOS) or EUTOS long-term survival (ELTS) scores at the time of the diagnosis. The proportions of patients who received each TKI were comparable in the AYA and older groups. Twenty-four (57.1%), 13 (31.0%) and 5 (11.9%) among total of 42 AYA group patients and 158 (49.7%), 85 (26.7%) and 75 (23.6%) among total of 318 older group patients were treated with imatinib, dasatinib and nilotinib, respectively, as the initial treatment. The median observation period was 76 months (range: 0–173 months) in the AYA group and 66 months (range: 4–202 months) in the older group ($p = .676$). The older group included one patient with platelet depletion ($< 100 \times 10^9/L$) due to liver cirrhosis, but not disease progression. In some cases, the Sokal, EUTOS, Hasford and ELTS score data were missing.

### Treatment response

The treatment responses of the AYA and older groups were comparable. The MMR rate at all timepoints during the follow-up period was 85.7% in the AYA group and 89.9% in the older group ($p = .42$). The DMR rate at all timepoints during the follow-up period was 42.9% in the AYA group and 60.4% in the older group ($p = .04$). The MMR rates at 12 months and 18 months did not differ between the AYA and older groups (MMR at 12 months: 42.9 and 58.2%, respectively, $p = .69$. MMR at 18 months: 61.9 and 67.0%, respectively, $p = .6$) (Figure 1). The cumulative incidence of MMR and DMR was comparable between the 2 groups (Figure 2).

### Long-term outcomes

The cumulative incidence of transformation to AP or BP in the AYA and older groups did not differ to a statistically significant extent ($p = .77$, Figure 3). The EFS and OS

---

**Table 1.** Patient characteristics according to the age at the time of treatment initiation.

| Factor                        | Age 18–29 (AYA) (N = 42) | Age 30–89 (N = 318) | p Value |
|-------------------------------|--------------------------|---------------------|---------|
| Median age                    | 25                       | 57                  | .0001   |
| Sex (male/female)             | 26/16                    | 195/123             | 1       |
| Spleen size below costal margin (cm) | 5.65 ± 7.61             | 1.16 ± 3.53         | <.0001  |
| WBC ($\times 10^9/L$)         | 102.1 (10.8–719.8)       | 31.8 (5.0–482.4)    | <.0001  |
| Haemoglobin (g/dL)            | 11.4 (5.8–16.1)          | 13.1 (5.0–18.8)     | .004    |
| Platelet ($\times 10^9/L$)    | 489 (118–2282)           | 506 (86–4352)       | .758    |
| PB (%)                        |                          |                     |         |
| Eosinophils                   | 2.0 (0–10)               | 2.0 (0–24)          | .765    |
| Basophils                     | 4.6 (0–17)               | 5.5 (0–19.5)        | .06     |
| Blasts                        | 0.5 (0–13.0)             | 0 (0–13.5)          | <.0001  |
| Lymphocytes                   | 4.3 (0–22.0)             | 8.5 (0–37.3)        | .008    |
| Sokal score, n (%)            |                          |                     |         |
| Low                           | 21 (50%)                 | 127 (40%)           | .009    |
| Intermediate                  | 5 (12%)                  | 123 (39%)           |         |
| High                          | 13 (31%)                 | 49 (15%)            |         |
| NE                            | 3 (7%)                   | 19 (6%)             |         |
| EUTOS score, n (%)            |                          |                     |         |
| Low                           | 30 (72%)                 | 263 (83%)           | .141    |
| High                          | 9 (21%)                  | 40 (12%)            |         |
| NE                            | 3 (7%)                   | 15 (5%)             |         |
| ELTS score, n (%)             |                          |                     |         |
| Low                           | 27 (64.3)                | 223 (70.1)          | .307    |
| Intermediate                  | 7 (16.7)                 | 66 (20.8)           |         |
| High                          | 4 (9.5)                  | 14 (4.4)            |         |
| NE                            | 4 (9.5)                  | 15 (4.7)            |         |
| Hasford score, n (%)          |                          |                     |         |
| Low                           | 23 (55%)                 | 120 (38%)           | .001    |
| Intermediate                  | 9 (21%)                  | 158 (50%)           |         |
| High                          | 7 (17%)                  | 25 (8%)             |         |
| NE                            | 3 (7%)                   | 15 (5%)             |         |
| Agent, n (%)                  |                          |                     |         |
| Imatinib                      | 24 (57.1%)               | 158 (49.7%)         | .231    |
| Dasatinib                     | 13 (31.0)                | 85 (26.7)           |         |
| Nilotinib                     | 5 (11.9)                 | 75 (23.6)           |         |
| Observation period, median (month) | 76 (0–173)             | 66 (4–202)          | .676    |

AYA: adolescents and young adults; PB: peripheral blood; EUTOS: European Treatment and Outcome Study; ELTS: EUTOS long-term survival; NE: not evaluated
rates were also comparable between the AYA and older groups. The 5-year EFS rate was 89.3% in the AYA group and 89.8% in the older group ($p = .87$) (Figure 4(A)). The 5-year OS rate was 92.3% in the AYA group, and 92.8% in the older group ($p = .96$) (Figure 4(B)). The rates of progression and leukaemia-related or leukaemia-unrelated death are shown in Table 2. The rates of leukaemia-unrelated death in the AYA and older groups were 4.8% and 4.7%, respectively (Table 2 near here).

The incidence and reasons for dose reduction or switching of initial TKIs

We investigated the incidence and reasons for dose reduction or switching of the initial TKIs. The rate of dose reduction in the AYA group was lower than that in the older group (4.7% vs. 39.6%). The reasons for intolerance in the AYA group were skin rash and oedema with imatinib. For the older group, the common reasons for intolerance were skin rash and patient request for imatinib, and pleural effusion with dasatinib (Supplementary Table 1).

After a median follow-up period of 67 months from the start of the initial treatment, 273 patients (75.8%) continued to receive their initial TKI. TKIs were more frequently switched in the AYA group than in the older group (57.1% vs. 19.8%) (Supplementary Table 2). Sixteen of the 24 imatinib-treated patients in the AYA group (66.7%) switched to a second-generation TKI, including nilotinib ($n = 7$) and dasatinib ($n = 8$) or IFN-α.
due to pregnancy \((n = 1)\). Seven of the 13 dasatinib-treated patients in the AYA group (76.9%) switched to other TKIs, including imatinib \((n = 1)\), nilotinib \((n = 3)\) or bosutinib \((n = 1)\), or registering in the STOP TKI study \((n = 2)\). One of the five nilotinib-treated patients in the AYA group (20%) switched to dasatinib. The reasons of switching from imatinib were resistance \((n = 5)\), the achievement of a DMR \((n = 5)\), registering in the STOP-TKI study \((n = 1)\), and intolerance due to unknown reasons \((n = 4)\). The reasons for switching from dasatinib or nilotinib were similar to those of imatinib.

Thirty-seven of the 158 imatinib-treated patients in the older group (23.4%) switched from imatinib to second-generation TKIs including nilotinib \((n = 19)\) and dasatinib \((n = 16)\), or third-generation TKIs bosutinib \((n = 2)\). Seventeen of the 85 dasatinib-treated patients in the older group (20%) switched to other TKIs, including imatinib \((n = 2)\), nilotinib \((n = 9)\) or bosutinib \((n = 6)\). Nine of the 75 nilotinib-treated patients in the older group (12%) switched to dasatinib \((n = 7)\) or imatinib \((n = 2)\). The reasons of switching from imatinib were resistance \((n = 7)\), the achievement of a DMR \((n = 5)\), muscle pain \((n = 1)\), renal dysfunction \((n = 2)\), pleural effusion \((n = 1)\), oedema \((n = 2)\), nausea \((n = 1)\), skin rash \((n = 1)\), diarrhoea \((n = 1)\), patient's request \((n = 1)\), registering in the STOP-TKI study \((n = 2)\) and intolerance due to unknown reasons \((n = 13)\). The reasons for switching from dasatinib were resistance \((n = 1)\), the achievement of a DMR \((n = 1)\), hepatic dysfunction \((n = 1)\), drug-induced lung injury \((n = 1)\), renal dysfunction \((n = 1)\), pleural effusion \((n = 4)\), skin rash \((n = 1)\), cytopenia \((n = 1)\), drug-induced colitis \((n = 1)\) and intolerance due to unknown reasons \((n = 5)\). The reasons for switching from nilotinib were resistance \((n = 2)\), oedema \((n = 1)\), IgG4-related sclerosing cholangitis \((n = 1)\), diabetes mellitus \((n = 1)\), heart failure \((n = 1)\), creatinine kinase elevation \((n = 1)\), chest pain \((n = 1)\) and intolerance due to unknown reasons \((n = 1)\).
Sub-analysis according to the TKI used for the initial therapy

Treatment response

Among patients who received imatinib as the initial therapy, no significant difference was seen in the MMR or DMR rates between the AYA group and older groups. The MMR rate at all timepoints during the follow-up period was 83.3% in the AYA group and 87.3% in the older group ($p = .53$). The DMR rate at all timepoints during the follow-up period was 45.8% in the AYA group and 60.8% in the older group ($p = .19$) (Figure 5(A)).

Furthermore, among patients treated with dasatinib or nilotinib as the initial therapy, no significant difference was seen in the MMR or DMR rates of the AYA and older groups. The MMR rate at all timepoints during the follow-up period was 88.9% in the AYA group and 92.5% in the older group ($p = .64$). The DMR rate...
at all timepoints during the follow-up period was 38.9% in the AYA group and 60.0% in the older group (p = .13) (Figure 5(B)).

**Long-term outcomes**

The EFS and OS rates of the AYA and older groups were comparable in patients who received imatinib and those who received second-generation TKIs as the initial therapy. Among the patients who were treated with imatinib as the initial therapy, the 5-year EFS rate was 91.3% in the AYA group and 89.5% in the older group (p = .49), the 5-year OS rate was 95.7% in the AYA group, and 92.0% in the older group (p = .37) (Figure 6(A,B)). Among patients treated with dasatinib or nilotinib as the initial therapy, the 5-year EFS rate was 87.5% in the AYA group and 90.3% in the older group (p = .38), the 5-year OS rate was 87.5% in the AYA group and 94.4% in the older group (p = .15) (Figure 6(C,D)).

**Discussion**

This study showed that the tumour burden at the diagnosis of CML-CP was higher in the AYA group, but that the prognosis was not worse in comparison to the older group.

There has been no definite conclusion on the clinical appearance or the outcome of AYA patients with CML-CP treated with TKIs, including second-generation...
TKIs. Several studies have examined the clinical characteristics and outcomes of AYA patients with CML-CP (Table 3). Kalmanti et al. assessed a total of 1524 CML-CP patients treated with imatinib or imatinib and interferon (IFN)-, and reported that AYA patients showed lower treatment response in AYA patients. Latagliata et al. assessed 206 CML-CP patients treated with imatinib and reported inferior MMR rates and shorter EFS in AYA patients [13]. In a cohort of the GIMEMA study, which analysed 774 patients treated with imatinib or dasatinib, the MMR rate of AYA patients was lower than that of older patients [14]. Both studies showed no significant difference in OS. In contrast, other studies have demonstrated not only a lower treatment response but also inferior long-term outcomes in AYA patients with CML-CP (Table 3 near here).

In these previous studies, most patients were treated with imatinib, and patients treated with a second-generation TKI as an initial treatment only accounted for a small percentage of the patients in each study. However, the ENEST1st study, which included 1091 CML-CP patients in an open-label, multicentre single-arm, prospective study on nilotinib, indicated that age did not have a relevant impact on the DMR rate [17].

We analysed AYA patients with CML-CP who were treated with imatinib or second-generation TKIs (nilotinib or dasatinib). In contrast to the previous studies, with the exception of the ENEST1st study, the MMR and EFS rates of the AYA group were not inferior to those of the older group. One of the possible reasons of this is that the rate of TKI switching was higher in the AYA group; 66.7 vs. 23.4% of imatinib-treated patients in the AYA group and the older group respectively (Supplementary Table 2). More treatment options were available during this study with the availability of second-generation TKIs. Seventy percent of the patients were treated after March 2009, when second-generation TKIs were approved in Japan. Other than resistance and intolerance, one of the reasons of switching from imatinib was the achievement of DMR. Achieving a deeper response faster has been associated with improved outcome in general. Inducing durable DMR may potentially lead to therapy discontinuation which is especially important for AYA patients, and second-generation TKIs induce higher rate of DMR [22,23]. According to the German CML-IV study, patients with a confirmed DMR by 4 years had a
higher rate of 8-year OS in comparison to patients with CCyR without an MMR by 4 years, and no patients who achieved a DMR experienced disease progression [23]. In another study, patients who achieved a DMR had higher rates of EFS and failure-free survival than patients who achieved a CCyR without a DMR [24].

Although it was not statistically significant, the factor that was associated with the inferior trend of DMR rate in the AYA group seems to be their higher tumour burden at the time of the diagnosis. The AYA group had a high rate of spleen enlargement and higher percentages of blasts in their PB in comparison to the older group, which confirmed the findings reported in previous studies [12,14,15,17]. In this study, the AYA group also had a significantly higher median WBC count, which was in line with the report by Latagliata et al. [13]. A possible explanation for the higher tumour burden of the AYA group at the diagnosis is the delayed diagnosis of this particular group in comparison to the older group who undergo routine check-ups, including blood-test, and who have more opportunities to undergo medical examinations as they often have comorbidities. Among the AYA group, these features were more prominent in patients who could not reach a DMR in comparison to those who could reach a DMR. At the time of the diagnosis, AYA patients who could not reach a DMR showed an enlarged spleen size (length below costal margin 8.6 vs. 0.8 cm, \( p = .0005 \)), higher WBC count (217.2 \( \times 10^9 \) vs. 59.9 \( \times 10^9 \) cells/L, \( p = .0005 \)), lower haemoglobin level (11.0 vs. 13.1 g/dL, \( p = .008 \)), and a lower percentage of lymphocytes in their PB (5.0 vs. 9.5\%, \( p = .04 \)) in comparison to those who could reach a DMR. These features may have prognostic value for AYA patients with CML-CP. Although the cumulative incidence of a DMR in the two groups was comparable, the cumulative incidence in the AYA group slowed down at around 80–100 months (Figure 2). The reason for this may be that the number of AYA patients was too low after the long follow-up period (approximately 8 months later). Furthermore, as we have previously reported that the introduction of second-generation TKIs may improve treatment outcomes in high-risk patients, they may indicate that it is appropriate for physicians to choose second-generation TKIs [25]. The incidence of dose reduction in the AYA group was lower than that in the older group (Supplementary Table 1), which suggests that they were better able to tolerate the initial dose than the older group; however, the incidence of switching TKIs was higher in the AYA group (Supplementary Table 2).

We need to understand the biological and non-biological features that may be related to the clinical outcomes of AYA patients. Biological features include parameters, such as the cytokine profile, genomic variants, the immunologic profile, TKI drug levels, half-life, and other factors. Non-biological features include adherence/compliance, psychosocial issues, and other factors. Within the data for this cohort, we address the fact that AYA patients presented with a larger tumour burden at the diagnosis of CML-CP. It is possible that these findings reflect robust cytokine signalling at the diagnosis in AYA patients, and these profiles will be important to investigate in a future study. On the other hand, the ELTS score, which is recommended by European LeukemiaNet 2020 [26] as a prognostic factor, was comparable between the 2 groups. In terms of genetic variants in each group, 3 of 42 AYA patients (7.1\%) and 29 of 318 older patients (9.1\%) had additional chromosomal abnormalities (ACA), and we cannot conclude whether this had an impact on the outcome because of the small number of patients in the study. Regarding the immunologic profile, successful TFR has been linked to increased natural killer (NK) cells and CD8 positive T-cells, decreased regulatory T-cells, myeloid-derived suppressor cells and mature (CD86+) plasmacytoid dendritic cells [27–31]. It would be interesting to explore the aforementioned immunologic profile as well as cytokine profile at diagnosis in each patient group to see if they have any effect on the outcome, therefore improving the prognosis and/or leading to the acquisition of a TFR. The pharmacokinetics may differ between AYA patients and older patients and this may affect the outcome. Patients with high imatinib exposure are reported to have better CCyR, MMR and EFS rates, and more adverse events, such as fluid retention, rash, myalgia and anaemia [32]. In this study, the age of patients was reported to be weakly correlated with trough levels; however, it is considered unlikely that this has clinical significance due to the large interpatient variability in imatinib plasma trough concentrations. In another study that analysed the pharmacokinetics of imatinib and the correlation with the response and safety, age was not found to significantly affect the volume of distribution and oral clearance covariates [33]. Compliance is an important issue, as non-compliance has been shown to negatively affect the treatment response and outcomes [34–37]; thus, it is important to support successful treatment and to develop strategies that facilitate the simple usage of TKIs. Any non-life-threatening symptoms (e.g. fluid retention, gastrointestinal symptoms, muscle cramps, joint pain, skin
rash and fatigue could be reasons for non-compliance. It is possible that AYA and middle-aged patients have poorer compliance due to socioeconomic reasons; however, this is mere speculation. On the other hand, older patients tend to have more comorbidities (e.g. cardiovascular events and malignancy), which may affect their compliance. A clinical study with a prospective cohort design is warranted to reach a conclusion regarding the relationship between adherence/compliance and the outcomes. It is also important to consider psychosocial issues, including moving due to a change of life stage, contraception, insurance or financial issues or QOL issues, which are characteristics of this particular population. One of the AYA patients died by suicide. We cannot conclude that this was related to the psychosocial character of the AYA population. A study assessing the QOL and symptom burden of patients receiving TKIs reported that there were no significant differences between the groups in terms of the effects on their daily life activities [38]. Combined with QOL issues, assessing the psychosocial burden of AYA patients may contribute to better management.

In conclusion, the tumour burden at the diagnosis of CML-CP is higher in AYA patients; however, the prognosis was not inferior in comparison to the older group. The MMR, EFS and OS rates of the AYA group were comparable to those in the older group. Understanding the biological and non-biological features of AYA patients with CML-CP on TKI therapy is essential for better management and may eventually improve outcomes.

Disclosure statement
NI received honoraria and speaker fees from Bristol-Myers Squibb, Novartis Pharma K.K., Otsuka Pharmaceutical and Pfizer Inc. MT received honoraria and speaker fees from Pfizer Inc. and Bristol-Myers Squibb. MK received honoraria and speaker fees from Bristol-Myers Squibb and Novartis Pharma K.K. TT and YH received honoraria from Bristol-Myers Squibb and Novartis Pharma K.K. TK received honoraria and speaker fees from Bristol-Myers Squibb, Novartis Pharma K.K. and Pfizer Inc. The remaining authors declare no competing financial interests. All authors have no non-financial conflicts of interest to declare.

T.N., N.I., M.T., M.I., E.S., T.T., K.S., H.F., I.F., S.T., Y.K., E.I., N.K., N.A., M.K., Y.H., T.K. designed and performed the research study; T.N. and Y.NF. analysed and interpreted data; T.N. and Y.NF. drafted the manuscript. All authors participated in critically revising the manuscript, and its final approval.

Funding
This work was supported by Bristol-Myers Squibb, Novartis Pharma K.K., Otsuka Pharmaceutical and Pfizer Inc.

ORCID
Yuriko Nishiyama-Fujita http://orcid.org/0000-0003-3338-0938
Tomonori Nakazato http://orcid.org/0000-0003-3579-4018
Norio Komatsu http://orcid.org/0000-0003-1880-9126

Data availability statement
The data that support the findings of this study are available from the corresponding author, TN, upon reasonable request.

References
[1] Hultcrantz M, Wilkes SR, Kristinsson SY, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a Population-Based study. J Clin Oncol. 2015; 33(20):2288–2295.
[2] Zebrack B, Mathews-Bradshaw B, Siegel S, et al. Quality cancer care for adolescents and young adults: a position statement. J Clin Oncol. 2010;28(32):4862–4867.
[3] Saloustros E, Stark DP, Michailidou K, et al. The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. ESMO Open. 2017;2(4): e000252.
[4] Adolescent and Young Adult Oncology Progress Review Group. Closing the gap: research and care imperatives for adolescents and young adults with cancer. Report of the Adolescent and Young Adult Oncology Progress Review Group. U.S. Department of Health and Human Services, National Institute of Health, National Cancer Institute. 2006. NIH Publication No. 06–6067.
[5] Ferrari A, Barr RD. International evolution in AYA oncology: Current status and future expectations. Pediatr Blood Cancer. 2017;64(9):e26528.
[6] Barr RD, Ferrari A, Ries L, et al. Cancer in adolescents and young adults: a narrative review of the current status and a view of the future. JAMA Pediatr. 2016; 170(5):495–501.
[7] Smith AW, Seibel NL, Lewis DR, et al. Next steps for adolescent and young adult oncology workshop: an update on progress and recommendations for the future. Cancer. 2016;122(7):988–999.
[8] Bleyer A, Tai E, Siegel S. Role of clinical trials in survival progress of American adolescents and young adults with cancer and lack thereof. Pediatr Blood Cancer. 2018;65(8):e27074.
[9] Coccia PF, Pappo AS, Beaupin L, et al. Adolescent and young adult oncology, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(1):66–97.
[10] Park EM, Rosenstein DL. Depression in adolescents and young adults with cancer. Dialogues Clin Neurosci. 2015;17(2):171–180.
[11] De R, Sutrtradhar R, Kurdyak P, et al. Incidence and predictors of mental health outcomes among survivors of adolescent and young adult cancer: a Population-
Based study using the IMPACT cohort. J Clin Oncol. 2021;39(9):1010–1019.

[12] Kalmanti L, Saussele S, Lauseker M, et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol. 2014;93(1):71–80.

[13] Latagliata R, Breccia M, Carmosino I, et al. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: the younger, the later, the worse? Eur J Haematol. 2018;101(5):578–584.

[14] Castagnetti F, Gugliotta G, Baccarani M, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26(1):185–192.

[15] Pemmaraju N, Kantarjian H, Shan J, et al. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012;97(7):1029–1035.

[16] Sakurai M, Mori T, Karigane D, et al. Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors. Int J Hematol. 2015;102(3):342–348.

[17] Giles FJ, Rea D, Rosti G, et al. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. 2017;143(8):1585–1596.

[18] Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884.

[19] Baccarani M, Castagnetti F, Gugliotta G, et al. Response definitions and European LeukemiaNet management recommendations. Best Pract Res Clin Haematol. 2009;22(3):331–341.

[20] Gray RJ. A class of K-Sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16(3):1141–1154.

[21] Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.

[22] Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709.

[23] Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014;32(5):415–423.

[24] Etienne G, Dulucq S, Nicolini FE, et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematologica. 2014;99(3):458–464.

[25] Sato E, Iriyama N, Tokuhira M, et al. Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score. Leuk Lymphoma. 2018;59(5):1105–1112.

[26] Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.

[27] Hsieh YC, Kirschner K, Copland M. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia. 2021;35(5):1229–1242.

[28] Ilander M, Olsson-Stromberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31(5):1108–1116.

[29] Mustjoki S, Ekbom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23(8):1398–1405.

[30] Irani YD, Hughes A, Clarson J, et al. Successful treatment-free remission in chronic myeloid leukemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol. 2020;191(3):433–441.

[31] Cayssials E, Jacomet F, Piccirilli N, et al. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. Br J Haematol. 2019;186(1):54–59.

[32] Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukaemia: a subanalysis of the IRIS study. Blood. 2008;111(8):4022–4028.

[33] Menon-Andersen D, Mondick JT, Jayaraman B, et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009;63(2):229–238.

[34] Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388.

[35] Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401–5411.

[36] Noens L, Hensen M, Kucmin-Bemelmans I, et al. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges. Haematologica. 2014;99(3):437–447.

[37] Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733–3736.

[38] Bostan H, Toptas T, Tanrikulu FP, et al. Quality of life and symptom burden with first- and second-generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(12):836–842.

[39] Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20(2):310–322.